Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent Β-thalassemia

NCT06280378 is registered in ClinicalTrials.gov with Kanglin Biotechnology (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT06280378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent Β-thalassemia
Lead sponsor
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 5, 2024
Completion date
May 31, 2027
Enrollment
41 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion-dependent beta-thalassemia